The prognostic relevance of the mitotic activity index in axillary lymph node-negative breast cancer

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

(2013) Josh J. Carlson et al.   BREAST CANCER RESEARCH AND TREATMENT

In Patients Younger Than Age 55 Years With Lymph Node–Negative Breast Cancer, Proliferation by Mitotic Activity Index Is Prognostically Superior to Adjuvant!

(2010) Tone Hoel Lende et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective multicenter comparison of proliferation and other prognostic factors in lymph node negative lobular invasive breast cancer

(2009) Einar Gudlaugsson et al.   BREAST CANCER RESEARCH AND TREATMENT

Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers

(2008) Jan P. A. Baak et al.   BREAST CANCER RESEARCH AND TREATMENT

Prognostic differences of World Health Organization–assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years

(2008) Ivar Skaland et al.   HUMAN PATHOLOGY